The global cell culture market is set to grow at a CAGR of 4.7% during the projected period. The market value is projected to increase from USD 27,911.3 million in 2024 to USD 44,593.1 million by 2034.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | USD 26,626.1 million |
| Estimated Global Cell Culture Market Size (2024E) | USD 27,911.3 million |
| Market Value (2034F) | USD 44,593.1 million |
| Value-based CAGR (2024 to 2034) | 4.7% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The swift adoption of cell culture techniques to manufacture viral vaccines and the increasing demand for sophisticated therapeutic pharmaceuticals fuel market growth. Developing novel three-dimensional cell cultured techniques and their subsequent usage in manufacturing vaccines and biopharmaceuticals are anticipated to propel the market's growth during the projected period.
Pharmaceutical and biotechnology companies invest heavily in research and development to create new vaccines, treatments, and testing kits. This, in turn, is set to propel demand through 2034.
The pandemic has heightened the demand for cell culture instruments, novel organoids, cell-based models, and high-throughput screening systems for medication development. Due to the outbreak's impact, the demand for bioreactors and culture systems for vaccine manufacturing and drug testing has also surged.
According to Centers for Disease Control and Prevention, over 59 million people in the United States are affected by arthritis. Similar trends have been observed regarding immunological disorders.
Chronic conditions surge demand for biopharmaceutical products such as hormones, antibodies, vaccines, and clotting factors, which are end products of cell cultured technologies. Thus, surging need for these products will benefit the target industry through 2034.
The market recorded a historic CAGR of 4.1% from 2019 to 2023. This was mostly due to the COVID-19 pandemic that created significant demand for biopharmaceuticals like vaccines and monoclonal antibodies.
In the next ten years, Future Market Insights analysts have predicted a CAGR of 4.7% for the global market. This can be attributed to a spike in chronic disease cases like cancer and diabetes.
According to the World Journal of Gastroenterology, cases of liver cirrhosis are on the rise, alongside an alarming increase in pancreatitis. Cell culture has the potential to address these concerns, as it is being proposed for hybrid artificial organs, particularly for the liver and endocrine pancreas. With the increase in organ failure, the demand for artificial organs is growing, propelling the market.
The demand for artificial organs is closely linked to development in tissue engineering and regenerative medicine. Cell culture plays a vital role in these areas by providing a controlled environment for the growth and differentiation of cells into functional tissues. It can also be utilized for culture-specific cells to replace damaged tissues, such as in the heart and liver, where regenerative capacity is limited.
Artificial organs made from cell culture are also used in drug testing and disease modeling. They offer a more accurate representation of human physiology than traditional cell culture models.
With the growing effort to introduce newer drugs, the need for reliable drug efficacy testing platforms is increasing, further propelling the demand for cell culture. These factors and government funding in regenerative medicine and research & development activities propel the cell culture market growth
Several factors are set to fuel sales growth during the assessment period. The increasing demand for cultured meat opens up possibilities for innovative and creative approaches to developing cell culture media.
The growing global population has increased the demand for high-quality food, shifting consumers towards sustainable solutions. Tissue-engineered animal meat presents a potential solution to these needs, involving the growth of cells under controlled environments and seeding them onto microcarriers and scaffolds to support 3D organization, differentiation, and maturation of various cell types.
The process of cultured meat production is intricate due to the complex structure of muscle, adipose tissue, and other vascular components. Initially, researchers focused on using pluripotent cells to produce different cells and tissues. However, there is a growing interest in utilizing adult stem cells (ASCs).
The global cultured meat industry has experienced a remarkable growth rate of 96% annually over the past decade. The industry's growth presents promising growth prospects for the market due to a large customer base and ongoing research and development efforts.
The lack of standardized biosimilar regulatory criteria across BRICS-TM agencies is a restrictive factor for the market. Biopharmaceutical companies strive to inflate their services globally but need regulatory consistency across different countries.
According to a National Library of Medicine report, the need for standardized biosimilar regulatory criteria across BRICS-TM agencies has resulted in multi-country development programs. This, in turn, increases the cost of introducing medicines within target markets, challenging the affordability of biosimilars and other biopharmaceutical products.
The limited availability of key raw materials and the need for well-established, fit-for-purpose manufacturing platforms hinder cell culture's repeatability, scalability, reproducibility, and comparability. Furthermore, the lack of harmonized regulation and quality challenges due to the absence of highly optimized culture conditions and poor operational expertise within emerging economies are restraining market growth.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The below table showcases revenues in terms of the top 5 leading countries, spearheaded by India and China. The countries will lead the market through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.0% |
| China | 7.9% |
| Germany | 3.4% |
| United Kingdom | 2.7% |
| India | 9.1% |
The United States is projected to exhibit a CAGR of 3.0% throughout the forecast period. It will account for a prominent global market share by the end of the forecast period. Several factors contribute to this growth, including surging demand for biopharmaceuticals like gene and stem cell therapies.
Increasing biopharmaceutical research and development activities in the United States are leading to a surge in the demand for cell culture products and services. Continuous progression in cell-cultured technologies, such as stem cell and organoid cultures, also positively impacts market growth.
China is set to record a CAGR of 7.9% from 2024 to 2034. Rising research and development activities in the industry have fueled the demand for cell cultured products for drug discovery, bioprocessing, and regenerative medicine applications.
Growing demand for biopharmaceuticals, regulatory approvals, and booming 3D cell culture market further propel demand in China. Similarly, increasing incidence of chronic diseases like cancer will benefit China market.
Germany is projected to exhibit a CAGR of 3.4% throughout the forecast period. Germany has a strong foothold in modern biotechnology and biopharmaceutical research, making it a leading region in the global cell culture market.
The presence of leading biotech companies, research institutions, and academic centers is also creating demand for cutting-edge cell cultured technologies and products in Germany. Germany's biopharmaceutical sector is surging, supported by government investments, favorable regulatory reforms, and a growing demand for innovative healthcare solutions. This growth has increased the need for developed cell cultured technologies and products in Germany.
The section below provides deeper insights into top segments and their growth rate. This information can help manufacturers and companies act accordingly and strengthen their presence in several lucrative regions.
Based on end-use, the biotechnology and pharmaceutical companies segment is poised to grow 6.0% CAGR through 2034. By phase, the clinical/research & development category will record a CAGR of 6.1% from 2024 to 2034.
| Product Type | Value CAGR (2024 to 2034) |
|---|---|
| Equipment | 3.6% |
| Cell Lines | 8.2% |
The equipment segment accounted for a prominent revenue share of 68.2% in 2023. This because due to its critical role in facilitating cell culture research, bioprocessing, and therapeutic development.
The demand for advanced supporting equipment, bioreactors, storage systems, and automation solutions underscores the importance of this segment in driving innovation, efficiency, and quality in cell culture applications. High adoption of these devices will play a key role in boosting sales growth.
On the other hand, the cell line segment is set to surge at a higher CAGR of 8.2% through 2034. This growth is attributed to the rise in research and development expenditures and the development of the life sciences sectors, particularly biopharmaceutical products. Furthermore, growing interest in stem cells and their growing uses in biotechnology research will boost segment growth.
| By Phase | Value CAGR (2024 to 2034) |
|---|---|
| Clinical/Research & Development | 6.1% |
| Commercial | 3.9% |
The commercial phase encompasses the large-scale production of biologics, vaccines, and other biopharmaceutical products using cell cultured technologies. The demand for these products in the pharmaceutical industry contributes significantly to the market share of the commercial phase.
The clinical/research & development phase is projected to surge at 6.1% CAGR through 2034. Cell cultured techniques are essential for stem cell cultivation and manipulation in regenerative medicine, tissue engineering, and cell-based therapies.
They are also essential in drug screening and toxicity testing, allowing controlled drug effects before animal models and clinical trials. Biopharmaceutical companies use large-scale cell culture systems for biological production, pouring need for clinical/research & development phase.
| End User | Value CAGR (2024 to 2034) |
|---|---|
| Biotechnology and Pharmaceutical Companies | 6.0% |
| Contract Research Development & Manufacturing Organizations (CDMO) | 4.8% |
Biotechnology and pharmaceutical companies have a considerable presence in the cell culture market, accounting for 41.5% of the market share in 2023. These companies heavily rely on cell cultured technology to produce biopharmaceuticals, vaccines, and other therapeutic proteins.
Cell culture models are used for preclinical testing, pharmacokinetics, and toxicology studies, contributing to developing and evaluating new drugs. The relationship between biotechnology and pharmaceutical companies and the market is characterized by a strong interdependence, with these companies serving as key factors of innovation and demand within the industry.
New product launches serve as a powerful promotional strategy for a company, offering a multifaceted approach to showcasing its commitment to innovation and scientific development. Leading companies are implementing tactical approaches, such as mergers and acquisitions and new product creation, to broaden their range of offerings and fortify their position. For instance,
The global market was valued at around USD 26,626.1 million in 2023.
The market is set to reach USD 27,911.3 million in 2024.
The market encompasses various consumables and equipment needed at various stages of cell culture techniques to comprehend cell biology and biochemistry.
Demand is slated to surge at a 4.7% CAGR by 2034.
The market is set to reach USD 44,593.1 million in 2034.
Thermo Fisher Scientific Inc., Danaher Corporation (Cepheid), and Agilent Technologies, Inc. are the key players.
Cell lines segment is estimated to hold a significant market share in 2024.
| Market Value for 2024 | USD 8,812.30 million |
|---|---|
| Forecast Value in 2034 | USD 31,540.90 million |
| CAGR (2024 to 2034) | 13.60% |
| Market Size in 2024 | USD 1,500 million |
|---|---|
| Market Value in 2034 | USD 2,241.8 million |
| Value-based CAGR (2024 to 2034) | 4.10% |
| Market Estimated Size in 2024 | USD 3.0 billion |
|---|---|
| Projected Market Value in 2034 | USD 3.9 billion |
| Value-based CAGR from 2024 to 2034 | 2.7% |
| Market Value for 2024 | USD 6,353.7 million |
|---|---|
| Forecast Market Value for 2034 | USD 8,374.50 million |
| Value-based CAGR from 2024 to 2034 | 2.80% |
Explore Life Science & Biotechnology Insights
View Reports
Cell Culture Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
